Epival and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Epival (divalproex sodium), especially for people who are female, 50-59 old, have been taking the drug for 10+ years also take Synthroid, and have Sleep disorder.

The phase IV clinical study analyzes which people have Weakness when taking Epival. It is created by eHealthMe based on reports of 968 people who have side effects when taking Epival from the FDA, and is updated regularly.

What is Epival?

Epival has active ingredients of divalproex sodium. It is often used in epilepsy. eHealthMe is studying from 1,088 Epival users. Check the latest studies of Epival.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,612 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 21, 2026

968 people reported to have side effects when taking Epival.
Among them, 45 people (4.65%) have Weakness.

Among these 45 people:

How long have people been on Epival when they have Weakness? *

What is the gender of people who have Weakness when taking Epival? *

female: 83.72 %
male: 16.28 %

What is the age of people who have Weakness when taking Epival? *

What are other drugs people take besides Epival? *

What are other side effects people have besides Weakness? *

Fatigue (feeling of tiredness): 21 people, 46.67%
Dizziness: 14 people, 31.11%
Nausea (feeling of having an urge to vomit): 12 people, 26.67%
Headache (pain in head): 11 people, 24.44%
Anaemia (lack of blood): 8 people, 17.78%
Stress And Anxiety: 8 people, 17.78%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 8 people, 17.78%
Crying: 7 people, 15.56%
Gait Disturbance: 7 people, 15.56%
Dyspnea (difficult or laboured breathing): 7 people, 15.56%

What are the existing conditions these people have? *

Sleep Disorder: 7 people, 15.56%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 6 people, 13.33%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 5 people, 11.11%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 5 people, 11.11%
Thyroid Diseases: 4 people, 8.89%
Chest Pain: 4 people, 8.89%
High Blood Cholesterol: 4 people, 8.89%
Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 8.89%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 3 people, 6.67%
Personality Disorder: 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Epival and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epival:

Epival (1,088 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Epival:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,612 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on divalproex sodium (the active ingredients of Epival) and Epival (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.